An HIV Patient with Hepatic Flare after the Initiation of HBV-active Antiretroviral Therapy

A 39-year-old man presented a CD4 T cell count of 78/μL and HIV-RNA at 6.6×105 copies/mL at his first medical examination. After the 58th day, we initiated HBV-active antiretroviral therapy. Three months after the start of antiretroviral therapy, he was diagnosed with hepatic flare on the basis of e...

Full description

Saved in:
Bibliographic Details
Published inInternal Medicine Vol. 51; no. 12; pp. 1623 - 1626
Main Authors Yoshida, Masaki, Hoshina, Tokio, Tamura, Kumi, Kawano, Shinji, Kato, Tetsuro, Sato, Fumiya, Nakazawa, Yasushi, Yoshikawa, Koji, Onodera, Shoichi, Hori, Seiji
Format Journal Article
LanguageEnglish
Published Japan The Japanese Society of Internal Medicine 01.01.2012
Subjects
Online AccessGet full text

Cover

Loading…
Abstract A 39-year-old man presented a CD4 T cell count of 78/μL and HIV-RNA at 6.6×105 copies/mL at his first medical examination. After the 58th day, we initiated HBV-active antiretroviral therapy. Three months after the start of antiretroviral therapy, he was diagnosed with hepatic flare on the basis of elevated AST and ALT levels without detecting HBV-DNA. Although after continuing the medication his AST and ALT levels increased to 700 IU/L and 1,400 IU/L, respectively, he showed improvement following a natural course and was discharged from hospital after the 169th day. This is a case of hepatic flare likely caused by immune reconstitution associated with resolved HBV infection.
AbstractList A 39-year-old man presented a CD4 T cell count of 78/ mu L and HIV-RNA at 6.6x105 copies/mL at his first medical examination. After the 58th day, we initiated HBV-active antiretroviral therapy. Three months after the start of antiretroviral therapy, he was diagnosed with hepatic flare on the basis of elevated AST and ALT levels without detecting HBV-DNA. Although after continuing the medication his AST and ALT levels increased to 700 IU/L and 1,400 IU/L, respectively, he showed improvement following a natural course and was discharged from hospital after the 169th day. This is a case of hepatic flare likely caused by immune reconstitution associated with resolved HBV infection.
A 39-year-old man presented a CD4 T cell count of 78/μL and HIV-RNA at 6.6×105 copies/mL at his first medical examination. After the 58th day, we initiated HBV-active antiretroviral therapy. Three months after the start of antiretroviral therapy, he was diagnosed with hepatic flare on the basis of elevated AST and ALT levels without detecting HBV-DNA. Although after continuing the medication his AST and ALT levels increased to 700 IU/L and 1,400 IU/L, respectively, he showed improvement following a natural course and was discharged from hospital after the 169th day. This is a case of hepatic flare likely caused by immune reconstitution associated with resolved HBV infection.
A 39-year-old man presented a CD4 T cell count of 78/µL and HIV-RNA at 6.6 × 10(5) copies/mL at his first medical examination. After the 58th day, we initiated HBV-active antiretroviral therapy. Three months after the start of antiretroviral therapy, he was diagnosed with hepatic flare on the basis of elevated AST and ALT levels without detecting HBV-DNA. Although after continuing the medication his AST and ALT levels increased to 700 IU/L and 1,400 IU/L, respectively, he showed improvement following a natural course and was discharged from hospital after the 169th day. This is a case of hepatic flare likely caused by immune reconstitution associated with resolved HBV infection.
Author Kawano, Shinji
Hoshina, Tokio
Tamura, Kumi
Nakazawa, Yasushi
Sato, Fumiya
Onodera, Shoichi
Hori, Seiji
Kato, Tetsuro
Yoshida, Masaki
Yoshikawa, Koji
Author_xml – sequence: 1
  fullname: Yoshida, Masaki
  organization: Department of Infectious Diseases and Infection Control, The Jikei University School of Medicine, Japan
– sequence: 2
  fullname: Hoshina, Tokio
  organization: Department of Infectious Diseases and Infection Control, The Jikei University School of Medicine, Japan
– sequence: 3
  fullname: Tamura, Kumi
  organization: Department of Infectious Diseases and Infection Control, The Jikei University School of Medicine, Japan
– sequence: 4
  fullname: Kawano, Shinji
  organization: Department of Infectious Diseases and Infection Control, The Jikei University School of Medicine, Japan
– sequence: 5
  fullname: Kato, Tetsuro
  organization: Department of Infectious Diseases and Infection Control, The Jikei University School of Medicine, Japan
– sequence: 6
  fullname: Sato, Fumiya
  organization: Department of Infectious Diseases and Infection Control, The Jikei University School of Medicine, Japan
– sequence: 7
  fullname: Nakazawa, Yasushi
  organization: Department of Infectious Diseases and Infection Control, The Jikei University School of Medicine, Japan
– sequence: 8
  fullname: Yoshikawa, Koji
  organization: Department of Infectious Diseases and Infection Control, The Jikei University School of Medicine, Japan
– sequence: 9
  fullname: Onodera, Shoichi
  organization: Department of Infectious Diseases and Infection Control, The Jikei University School of Medicine, Japan
– sequence: 10
  fullname: Hori, Seiji
  organization: Department of Infectious Diseases and Infection Control, The Jikei University School of Medicine, Japan
BackLink https://www.ncbi.nlm.nih.gov/pubmed/22728503$$D View this record in MEDLINE/PubMed
BookMark eNqFkU9rGzEQxUVIiO0kX6Ho2Ms6-re72qMbmtgQcA5pLj0ss_KoVlhrXUlO8bevjF0fSqGXGYb5zTx4b0Iu_eCREMrZVPCquXc-YfDQb3DljPM4Lfm0FkpdkDGXqilqIctLMmYN14XIZUQmMb4zJnXdiGsyEqIWumRyTL7PPJ0v3ugLJIc-0V8urekct3k09LGHgBRsFqNpjXThXXJ5M3g6WDr_8laASe4D6cwnFzCF4cMF6OnrGgNs97fkykIf8e7Ub8i3x6-vD_Piefm0eJg9F6asWCpAgjC2QqVt3XFEZTXoijVKV9xKqS0XbCWbrrMro5S1jeKlNIClYh0qVssb8vn4dxuGnzuMqd24aLDvweOwiy0XUnNe85r9H2VCiFIzJTOqj6gJQ4wBbbsNbgNhn6H2kEL7dwptydtDCvn000ll1-Xl-fCP7RlYHoH3mOAHngEI2fYe__mZi0M9SZxJs4bQope_AWc-pu4
CitedBy_id crossref_primary_10_1007_s11901_014_0238_2
crossref_primary_10_1007_s40278_013_0766_5
Cites_doi 10.1007/s11908-005-0068-z
10.1097/QAD.0b013e328013db9c
10.1016/j.clinre.2011.07.018
10.1097/01.aids.0000161769.06158.8a
10.1086/428502
10.1111/j.1872-034X.2007.00263.x
10.1073/pnas.120055097
10.1016/S0140-6736(02)11913-1
10.1086/597276
10.1086/377135
10.1016/S1473-3099(05)70141-9
10.1046/j.1468-1293.2000.00012.x
10.1097/01.aids.0000232232.41877.2a
10.1007/s10165-011-0521-9
10.7326/0003-4819-146-2-200701160-00003
10.1086/499356
10.1097/00002030-200012220-00011
ContentType Journal Article
Copyright 2012 by The Japanese Society of Internal Medicine
Copyright_xml – notice: 2012 by The Japanese Society of Internal Medicine
DBID CGR
CUY
CVF
ECM
EIF
NPM
AAYXX
CITATION
7X8
7U9
H94
DOI 10.2169/internalmedicine.51.7244
DatabaseName Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
CrossRef
MEDLINE - Academic
Virology and AIDS Abstracts
AIDS and Cancer Research Abstracts
DatabaseTitle MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
CrossRef
MEDLINE - Academic
AIDS and Cancer Research Abstracts
Virology and AIDS Abstracts
DatabaseTitleList AIDS and Cancer Research Abstracts

MEDLINE - Academic
MEDLINE
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
EISSN 1349-7235
EndPage 1626
ExternalDocumentID 10_2169_internalmedicine_51_7244
22728503
article_internalmedicine_51_12_51_51_7244_article_char_en
Genre Journal Article
Case Reports
GroupedDBID ---
.55
29J
2WC
3O-
53G
5GY
7.U
AAPBV
AAUGY
ACPRK
ADBBV
ADRAZ
AENEX
AFRAH
ALMA_UNASSIGNED_HOLDINGS
AOIJS
BAWUL
CS3
DIK
DU5
EBS
EJD
EMOBN
F5P
HYE
JSF
JSH
M48
M~E
OK1
P2P
RJT
RNS
RPM
RZJ
TKC
TR2
X7M
XSB
CGR
CUY
CVF
ECM
EIF
NPM
PGMZT
AAYXX
CITATION
7X8
7U9
H94
ID FETCH-LOGICAL-c560t-a3a2cf6e48f7b1ee4f8a86094861f338f120d39bbfdc44ff94153cae540be4073
ISSN 0918-2918
IngestDate Sat Jun 22 20:24:53 EDT 2024
Fri Jun 28 15:04:36 EDT 2024
Fri Aug 23 00:46:17 EDT 2024
Sat Sep 28 08:33:37 EDT 2024
Thu Aug 17 20:29:16 EDT 2023
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 12
Language English
LinkModel OpenURL
MergedId FETCHMERGED-LOGICAL-c560t-a3a2cf6e48f7b1ee4f8a86094861f338f120d39bbfdc44ff94153cae540be4073
Notes ObjectType-Case Study-2
SourceType-Scholarly Journals-1
ObjectType-Feature-4
content type line 23
ObjectType-Report-1
ObjectType-Article-3
ObjectType-Article-2
ObjectType-Feature-1
OpenAccessLink https://www.jstage.jst.go.jp/article/internalmedicine/51/12/51_51.7244/_article/-char/en
PMID 22728503
PQID 1022258043
PQPubID 23479
PageCount 4
ParticipantIDs proquest_miscellaneous_1238117170
proquest_miscellaneous_1022258043
crossref_primary_10_2169_internalmedicine_51_7244
pubmed_primary_22728503
jstage_primary_article_internalmedicine_51_12_51_51_7244_article_char_en
PublicationCentury 2000
PublicationDate 2012-01-01
PublicationDateYYYYMMDD 2012-01-01
PublicationDate_xml – month: 01
  year: 2012
  text: 2012-01-01
  day: 01
PublicationDecade 2010
PublicationPlace Japan
PublicationPlace_xml – name: Japan
PublicationTitle Internal Medicine
PublicationTitleAlternate Intern. Med.
PublicationYear 2012
Publisher The Japanese Society of Internal Medicine
Publisher_xml – name: The Japanese Society of Internal Medicine
References 15. Watanabe K, Takase K, Ohno S, Ideguchi H, Nozaki A, Ishigatsubo Y. Reactivation of hepatitis B virus in a hepatitis B surface antigen-negative patient with rheumatoid arthritis treated with methotrexate. Mod Rheumatol 2011 Sep 8 [Epub ahead of print].
1. Lohse N, Hansen AB, Pedersen G, et al. Survival of persons with and without HIV infection in Denmark, 1995-2005. Ann Intern Med 146: 87-95, 2007.
17. French MA, Lenzo N, John M, et al. Immune restoration disease after the treatment of immunodeficient HIV-infected patients with highly active antiretroviral therapy. HIV Med 1: 107-115, 2000.
18. Shelburne SA, Visnegarwala F, Darcourt J, et al. Incidence and risk factors for immune reconstitution inflammatory syndrome during highly active antiretroviral therapy. AIDS 19: 399-406, 2005.
10. Cicconi P, Cozzi-Lepri A, Phillips A, et al; ICoNA Study Group. Is the increased risk of liver enzyme elevation in patients co-infected with HIV and hepatitis virus greater in those taking antiretroviral therapy? AIDS 21: 599-606, 2007.
13. Koo YX, Tan DS, Tan IB, Tao M, Lim ST. Hepatitis B virus reactivation in a patient with resolved hepatitis B virus infection receiving maintenance rituximab for malignant B-cell lymphoma. Ann Intern Med 150: 655-656, 2009.
6. Koike K, Kikuchi Y, Kato M, et al. Prevalence of hepatitis B virus infection in Japanese patients with HIV. Hepatol Res 38: 310-314, 2008.
12. Núñez M, Soriano V. Management of patients co-infected with hepatitis B virus and HIV. Lancet Infect Dis 5: 374-382, 2005.
3. Ratnam I, Chiu C, Kandala NB, Easterbrook PJ. Incidence and risk factors for immune reconstitution inflammatory syndrome in an ethnically diverse HIV type 1-infected cohort. Clin Infect Dis 42: 418-427, 2006.
2. Murdoch DM, Venter WD, Van Rie A, Feldman C. Immune reconstitution inflammatory syndrome (IRIS): review of common infectious manifestations and treatment options. AIDS Res Ther 4: 9, 2007.
4. Thio CL, Seaberg EC, Skolasky R Jr, et al. HIV-1, hepatitis B virus, and risk of liver-related mortality in the Multicenter Cohort Study (MACS). Lancet 360: 1921-1926, 2002.
19. Lascar RM, Lopes AR, Gilson RJ, et al. Effect of HIV infection and antiretroviral therapy on hepatitis B virus (HBV)-specific T cell responses in patients who have resolved HBV infection. J Infect Dis 191: 1169-1179, 2005.
14. Papamichalis P, Alexiou A, Boulbou M, Dalekos GN, Rigopoulou EI. Reactivation of resolved hepatitis B virus infection after immunosuppression: is it time to adopt pre-emptive therapy? Clin Res Hepatol Gastroenterol 36: 84-93, 2011.
16. Kato M, Atsumi T, Kurita T, et al. Hepatitis B virus reactivation by immunosuppressive therapy in patients with autoimmune diseases: risk analysis in Hepatitis B surface antigen-negative cases. J Rheumatol 38: 2209-2214, 2011.
9. Kress KD. Antiretroviral-associated hepatotoxicity. Curr Infect Dis Rep 7: 103-107, 2005.
7. Filippini P, Coppola N, Pisapia R, et al. Impact of occult hepatitis B virus infection in HIV patients naive for antiretroviral therapy. AIDS 20: 1253-1260, 2006.
20. Crane M, Oliver B, Matthews G, et al. Immunopathogenesis of hepatic flare in HIV/hepatitis B virus (HBV)-coinfected individuals after the initiation of HBV-active antiretroviral therapy. J Infect Dis 199: 974-981, 2009.
11. Sulkowski MS, Thomas DL, Chaisson RE, Moore RD. Hepatotoxicity associated with antiretroviral therapy in adults infected with human immunodeficiency virus and the role of hepatitis C or B virus infection. JAMA 283: 74-80, 2000.
8. den Brinker M, Wit FW, Wertheim-van Dillen PM, et al. Hepatitis B and C virus co-infection and the risk for hepatotoxicity of highly active antiretroviral therapy in HIV-1 infection. AIDS 14: 2895-2902, 2000.
5. Kellerman SE, Hanson DL, McNaughten AD, Fleming PL. Prevalence of chronic hepatitis B and incidence of acute hepatitis B infection in human immunodeficiency virus-infected subjects. J Infect Dis 188: 571-577, 2003.
11
12
13
14
15
16
17
18
19
1
2
3
4
5
6
7
8
9
10
References_xml – ident: 2
– ident: 9
  doi: 10.1007/s11908-005-0068-z
– ident: 10
  doi: 10.1097/QAD.0b013e328013db9c
– ident: 13
  doi: 10.1016/j.clinre.2011.07.018
– ident: 17
  doi: 10.1097/01.aids.0000161769.06158.8a
– ident: 18
  doi: 10.1086/428502
– ident: 6
  doi: 10.1111/j.1872-034X.2007.00263.x
– ident: 12
  doi: 10.1073/pnas.120055097
– ident: 4
  doi: 10.1016/S0140-6736(02)11913-1
– ident: 15
– ident: 19
  doi: 10.1086/597276
– ident: 5
  doi: 10.1086/377135
– ident: 11
  doi: 10.1016/S1473-3099(05)70141-9
– ident: 16
  doi: 10.1046/j.1468-1293.2000.00012.x
– ident: 7
  doi: 10.1097/01.aids.0000232232.41877.2a
– ident: 14
  doi: 10.1007/s10165-011-0521-9
– ident: 1
  doi: 10.7326/0003-4819-146-2-200701160-00003
– ident: 3
  doi: 10.1086/499356
– ident: 8
  doi: 10.1097/00002030-200012220-00011
SSID ssj0038792
Score 1.9719204
Snippet A 39-year-old man presented a CD4 T cell count of 78/μL and HIV-RNA at 6.6×105 copies/mL at his first medical examination. After the 58th day, we initiated...
A 39-year-old man presented a CD4 T cell count of 78/µL and HIV-RNA at 6.6 × 10(5) copies/mL at his first medical examination. After the 58th day, we initiated...
A 39-year-old man presented a CD4 T cell count of 78/ mu L and HIV-RNA at 6.6x105 copies/mL at his first medical examination. After the 58th day, we initiated...
SourceID proquest
crossref
pubmed
jstage
SourceType Aggregation Database
Index Database
Publisher
StartPage 1623
SubjectTerms Adult
Alanine Transaminase - blood
Anti-HIV Agents - therapeutic use
antiretroviral therapy
Antiviral Agents - adverse effects
Aspartate Aminotransferases - blood
CD4 antigen
CD4 Lymphocyte Count
hepatic flare
Hepatitis B - complications
Hepatitis B - drug therapy
Hepatitis B - immunology
Hepatitis B - virology
Hepatitis B virus
Hepatitis B virus - genetics
Hepatitis B virus - isolation & purification
HIV Infections - complications
HIV Infections - immunology
HIV Infections - virology
Hospitals
Human immunodeficiency virus
human immunodeficiency virus (HIV)
Humans
Immune reconstitution
immune reconstitution inflammatory syndrome (IRIS)
Immune Reconstitution Inflammatory Syndrome - etiology
Immune Reconstitution Inflammatory Syndrome - immunology
Immune Reconstitution Inflammatory Syndrome - virology
Infection
Liver
Lymphocytes T
Male
resolved hepatitis B virus
RNA, Viral - blood
Viral Load
Title An HIV Patient with Hepatic Flare after the Initiation of HBV-active Antiretroviral Therapy
URI https://www.jstage.jst.go.jp/article/internalmedicine/51/12/51_51.7244/_article/-char/en
https://www.ncbi.nlm.nih.gov/pubmed/22728503
https://search.proquest.com/docview/1022258043
https://search.proquest.com/docview/1238117170
Volume 51
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
ispartofPNX Internal Medicine, 2012, Vol.51(12), pp.1623-1626
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lj9MwELbKgtBeEG-6PGQkblVK_EjiHAsCFVbLhS5axCGyU3u3habVNhWPX8_4kTS72iLgErWxHSczn8fj8cwYoRcpT4SMZRmVRPKIKx5HMknhbxITHYupUNLaO44-pONj_v4kOen1fnS8lja1Gpa_rowr-R-uwj3gq42S_QfOtg-FG_Ab-AtX4DBc_4rHo2owhuVbyI3qbapneuWSsJpv1qfLHwFulcuZ9RJq9cPxq0-RdKJuAKQFsVdb04IN1q87aQbmWzd3p7U2G_FWLZ0sv_50ZlbrWdqxJ3xers9mU-njgNagn7bAsQU-Ag3aevcvbzNYbM59YNpm0dY-lN-lOxV88BFazWdd64Rz82isE9pLVMbzKKM-J0kjckOO2QAt2hGgJPXhx5clOyWpTYw6Cx_cfO8wIcOM-gySHYavFo7jlGZUJDHbznWtB2JTdA1dpyCi3Ab_u8NmDmciy4Pfl-345a5ubSrp8KALes2NOaj2p3r3qsVpL5Pb6FZYduCRx9Ad1NPVXXTzKHR0D30ZVRighAOUsIUSDlDCDkrYQQkDPPAWSnhp8BZK-CKUcIDSfXT89s3k9TgK527ACE3jOpJM0tKkmguTKaI1N0KKNM65SIlhTBhC4ynLlTLTknNjclACWSk1KP9Kc5gzHqC9alnpRwjH0lAltc6ngvGSESVKo6CB0DLNc532EWmoVqx8epUClqWW6MVlohcJKSzR-2jsydu2CAPwyhaE2mto2ta0IY0gQfroecOgAsSq3SuTlV5u1oU3hIiYsz_UseouyUgW99FDz932lRpYHOwseYz2twPmCdqrzzf6KSi4tXrmsPgbVWyrhg
link.rule.ids 315,783,787,27936,27937
linkProvider Flying Publisher
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=An+HIV+patient+with+hepatic+flare+after+the+initiation+of+HBV-active+antiretroviral+therapy&rft.jtitle=Internal+medicine+%28Tokyo%2C+1992%29&rft.au=Yoshida%2C+Masaki&rft.au=Hoshina%2C+Tokio&rft.au=Tamura%2C+Kumi&rft.au=Kawano%2C+Shinji&rft.date=2012-01-01&rft.eissn=1349-7235&rft.volume=51&rft.issue=12&rft.spage=1623&rft_id=info:doi/10.2169%2Finternalmedicine.51.7244&rft_id=info%3Apmid%2F22728503&rft.externalDocID=22728503
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0918-2918&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0918-2918&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0918-2918&client=summon